Skip to content
    Real-World Studies

    ddPCR ctDNA Monitoring Anticipates Progression Ahead of Imaging in NSCLC and Breast Cancer

    Knebel et alCancer Medicine

    In a real-world, longitudinal study conducted at a Brazilian oncology reference center, serial circulating tumor DNA (ctDNA) monitoring utilizing digital PCR (ddPCR) was evaluated for tracking treatment response and detecting acquired resistance in 48 metastatic cancer patients, comprising 42 individuals with EGFR-mutant non-small cell lung cancer (NSCLC) and 6 with HR+/HER2-negative metastatic breast cancer (MBC).
    Among the NSCLC cohort, serial plasma ddPCR identified the EGFR T790M resistance mutation in 48.4% of patients experiencing progression on first- or second-generation tyrosine kinase inhibitors (TKIs). In patients receiving third-generation TKIs, EGFR C797S emerged as the primary mechanism of acquired resistance at 47%, alongside PIK3CA and BRAF mutations and ERBB2/EGFR amplifications. Notably, serial molecular tracking anticipated radiological progression by approximately 5 months, while early molecular response—evidenced by mutation clearance in plasma—consistently preceded radiological tumor response.
    In the HR+/HER2-negative MBC cohort, hotspot ESR1 mutations (including D538G, L536R, and Y537S) were detected in 50% of patients. Longitudinal shifts in ctDNA fractional abundance predicted disease progression up to 9 months prior to confirmation on standard imaging.
    Although limited by a modest overall sample size and a particularly small breast cancer cohort, these real-world findings demonstrate that ddPCR-based liquid biopsy provides clinically actionable lead time over conventional imaging, potentially supporting timely therapeutic adjustments in precision oncology.

    Key Takeaways

    • In metastatic EGFR-mutant NSCLC, serial ddPCR ctDNA monitoring anticipated radiological progression by approximately 5 months, detecting EGFR T790M in 48.4% of patients failing first- or second-generation TKIs and EGFR C797S in 47% of those progressing on third-generation TKIs.
    • In HR+/HER2-negative metastatic breast cancer, shifts in ctDNA fractional abundance identified hotspot ESR1 mutations in 50% of patients and detected disease progression up to 9 months prior to radiological confirmation.
    • Early molecular response defined by ctDNA mutation clearance preceded objective radiological response during targeted treatment.